SEC Filing Summary: Form 6-K
Business Context and Reporting Period
This Form 6-K is filed by Galapagos NV (a foreign private issuer), not Lakefront Biotherapeutics NV as indicated in the request metadata. The filing covers the month of December 2025, specifically dated December 18, 2025. The report serves to incorporate a press release (Exhibit 99.1) by reference into the company's existing Registration Statements on Form S-8.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or earnings data.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this text. The filing solely references the issuance of a press release on December 18, 2025.
Guidance, Outlook, and Risks
The filing incorporates a press release by reference but does not summarize its content within the Form 6-K text itself. Consequently, specific guidance, management commentary, risks, contingencies, or unusual items are not detailed in this document. The text notes that quotes from Dr. Rohit Aggarwal and Henry Gosebruch in the attached press release are excluded from incorporation by reference.
Key Facts for Investor Verification
- Verify the correct registrant name is Galapagos NV, not Lakefront Biotherapeutics NV.
- Review the attached Exhibit 99.1 (Press Release dated December 18, 2025) for the actual substance of the announcement.
- Note that specific quotes from Dr. Rohit Aggarwal and Henry Gosebruch are explicitly excluded from incorporation into the S-8 registration statements.
- Confirm the filing date is December 18, 2025, for the month of December 2025.